Business Wire

Aleph Farms Submits First Ever Application for Cultivated Meat in Europe

26.7.2023 11:00:00 EEST | Business Wire | Press release

Share

Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory approval to the Swiss Federal Food Safety and Veterinary Office (FSVO) with the goal of selling the world’s first cultivated beef steaks under the Aleph Cuts brand in Switzerland. The submission is part of Aleph’s collaboration with Migros, Switzerland’s largest food enterprise, which has been instrumental in assessing the country’s specific regulatory approval process.

Aleph Farms is leveraging the expertise and infrastructure of leaders in food production, including Migros, which first invested in the company in 2019, to help accelerate scale-up, go-to-market activities and commercialization of Aleph Cuts worldwide. Together, Aleph and Migros have since conducted extensive consumer research in Switzerland and navigated the intricacies of the country’s regulatory landscape for novel foods. As part of their agreement, the two companies will continue to develop a go-to-market strategy that involves distribution and commercialization of Aleph Cuts through fine dining food service channels in Switzerland.

“Food systems affect everyone, and it will take a coordinated effort between regulators, innovators and incumbents to ensure food security in a way that helps humanity live within its planetary boundaries,” said Didier Toubia, Co-Founder and CEO of Aleph Farms. “At Aleph Farms, we carefully consider partnerships that reflect our core values and sustainability commitments. Together with Migros, we are establishing the cow cell as the third category of food products from cattle, alongside beef and milk. We look forward to working closely with Switzerland's Federal Food Safety and Veterinary Office to enable access to both high-quality nutrition and world-changing innovation.”

Switzerland is a country with a high affinity for innovation. According to research conducted jointly by Aleph Farms and Migros, 74% of Swiss consumers are open to trying cultivated meat and are motivated to try it chiefly by curiosity and a desire to align with principles like sustainability and animal welfare.

Alongside sustainable animal agriculture, cellular agriculture can help increase resilience and stability in the supply of animal proteins and fats to diners in Switzerland. In addition, acceptance by Swiss consumers – known for a quality-conscious attitude towards food – can contribute further to cultivated meat’s growing momentum worldwide.

Later this year, Aleph Farms plans to launch Aleph Cuts in Singapore and Israel in limited quantities and offer exclusive tasting experiences curated with select partners, pending regulatory approvals. Aleph’s regulatory team is working in similar fashion with regulatory authorities in numerous markets around the world, including Switzerland, in order to ensure compliance with respective safety requirements.

About Aleph Farms

Aleph Farms, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare in our food systems by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable animal agriculture.

Founded in 2017, the company unveiled the world’s first cultivated thin-cut beef steak in 2018, the world’s first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow.

For its contributions to climate leadership including a net zero commitment made in 2020, the company has received top accolades from the World Economic Forum and the United Nations.

For more information, follow Aleph Cuts on Instagram and Facebook, Aleph Farms on Twitter and Linkedin, or visit www.aleph-farms.com. Access our press kit here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Natalee Gibson
alephfarms@songuepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye